Silence Therapeutics plc
OTC: SLNCF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Iain Gladstone Ross
- Employees
- 116
- Headquarters
- London, United Kingdom
- IPO year
- 2012
- Market cap
- $311.7M
- Website
- https://www.silence-therapeutics.com
Loading SLNCF…
Loading profile data…Frequently asked questions about SLNCF
What does Silence Therapeutics plc (SLNCF) do?
Silence Therapeutics plc, a biotechnology firm headquartered in London, United Kingdom, is dedicated to the discovery and advancement of pioneering ribonucleic acid (RNA) therapeutics. Its research and development efforts span key areas such as blood disorders, cardiovascular health, and other uncommon and metabolic ailments. Central to the comp...
Where does SLNCF trade?
Silence Therapeutics plc (SLNCF) trades on the Other OTC.
What sector is SLNCF in?
Silence Therapeutics plc (SLNCF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Silence Therapeutics plc?
Iain Gladstone Ross is the chief executive officer of Silence Therapeutics plc (SLNCF).
Where is Silence Therapeutics plc headquartered?
Silence Therapeutics plc is headquartered in United Kingdom.
Does SLNCF pay a dividend?
Silence Therapeutics plc (SLNCF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SLNCF go public?
Silence Therapeutics plc (SLNCF) completed its initial public offering in 2012.